Microarray patch (MAP) technologies can address the need for improved presentations of vaccines. The PATH Center of Excellence for MAP Technology is advancing MAP development for high priority needs in low- and middle-income countries (LMICs). The development of a vaccine MAP depends on a number of technical, clinical, regulatory, and commercialization factors. To aid in selecting an appropriate antigen, this document overviews key antigen qualities that impact the likelihood of successful technical development for a vaccine MAP.